- Stocks
- Pharma & Healthcare
- Auro Labs
Auro Labs share price
NSE: AUROLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Auro Labs at a glance
With a market capitalisation of ₹156 Cr, it ranks 2423rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 4.3% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹10 Cr (+32.8% year on year) and net profit ₹1 Cr (+148.7%), on a standalone basis. Promoters held 52.40% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹156 CrRank 2423 on NSE
- Price to book
- 3.34×FY25
- EPS (TTM)
- ₹5.67to Q4 FY26
- ROE
- 4.3%FY25
- ROCE
- 3.8%FY25
- Debt to equity
- 0.99FY25
- Net profit margin
- 9.5%FY25
- Book value / share
- ₹68.94FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Auro Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹7 Cr | ₹3 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr |
| Revenue YoY | −43.8% | −76.9% | −83.0% | −38.6% | −51.6% | +185.2% | +207.9% | +32.8% |
| Net profit | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
| Net profit YoY | +5.6% | −81.7% | −98.2% | −83.2% | −114.7% | +100.0% | +3,800.0% | +148.7% |
| Net margin | 13.1% | 11.6% | 1.6% | 5.3% | −4.0% | 8.1% | 20.8% | 9.9% |
| EPS | ₹1.21 | ₹0.57 | ₹0.08 | ₹0.63 | −₹0.17 | ₹1.15 | ₹3.13 | ₹1.56 |
Auro Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹44 Cr | ₹54 Cr | ₹51 Cr | ₹53 Cr | ₹54 Cr | ₹19 Cr |
| Operating profit | ₹6 Cr | ₹11 Cr | ₹4 Cr | ₹3 Cr | ₹10 Cr | ₹2 Cr |
| Net profit | ₹4 Cr | ₹7 Cr | ₹3 Cr | ₹2 Cr | ₹8 Cr | ₹2 Cr |
| EPS (₹) | ₹6.51 | ₹11.52 | ₹4.56 | ₹3.92 | ₹12.50 | ₹2.95 |
| Cash from operations | ₹9 Cr | ₹6 Cr | −₹7 Cr | ₹3 Cr | ₹19 Cr | ₹6 Cr |
| Total debt | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹18 Cr | ₹31 Cr |
| Shareholders' equity | ₹22 Cr | ₹29 Cr | ₹32 Cr | ₹34 Cr | ₹42 Cr | ₹43 Cr |
Auro Labs shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 52.18% | 52.18% | 52.18% | 52.18% | 52.40% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 47.82% | 47.82% | 47.82% | 47.82% | 47.59% |
Auro Labs vs peers
The listed Pharma & Healthcare companies nearest to Auro Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| NATCAPSUQNatural Capsules | ₹162.00 | +1.25% | −32.2% | ₹169 Cr | — | — |
| PANCHSHEELPanchsheel Org | — | — | — | ₹159 Cr | — | — |
| AUROLABAuro Labs | — | — | — | ₹156 Cr | — | — |
| KIMIABLKimia Bio | — | — | — | ₹152 Cr | — | — |
| SMRUTHIORGSmruthi Organic | — | — | — | ₹135 Cr | — | — |
Ask anything about Auro Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against AUROLAB's own history. Try: “Why has AUROLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on AUROLAB over five years” · “Compare AUROLAB with BALPHARMA on margins and valuation”
Frequently asked questions about Auro Labs
What is the market cap of Auro Labs?
Auro Labs' market capitalisation is ₹156 Cr (₹156 Cr) at the 19 Oct 2026 close, ranking 2423rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Auro Labs?
Return on equity was 4.3% in FY25 and return on capital employed was 3.8% in FY25 (standalone figures).
Is Auro Labs a debt-free company?
No. Auro Labs' debt-to-equity ratio was 0.99 in FY25, with total debt of ₹31 Cr.
What were Auro Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Auro Labs reported revenue of ₹10 Cr, +32.8% year on year, and net profit of ₹1 Cr, +148.7% year on year.
What is the shareholding pattern of Auro Labs?
As of 30 Jun 2026: promoters 52.40%, domestic institutions 0.01%, non-institutions 47.59%.
Who are Auro Labs' competitors?
The listed Pharma & Healthcare companies closest to Auro Labs by market cap are Bal Pharma, Vaidya Sane Ayu, Natural Capsules, Panchsheel Org, Kimia Bio and Smruthi Organic.
Is Auro Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Auro Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AUROLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text